The paradigm of surface-expressed programmed death ligand 1 (PDL1) signalling to
immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to …

Cardiovascular disease and cancer are the 2 leading causes of death worldwide. Emerging
evidence suggests common mechanisms between cancer and cardiovascular disease …

Immune-checkpoint inhibitors (ICI) have transformed oncological therapy. Up to 20% of all
non-small cell lung cancers (NSCLCs) show durable responses upon treatment with ICI …

Currently, immune checkpoint blockade (ICB) therapies that target the programmed cell
death ligand-1 (PD-L1) have been used as revolutionary cancer treatments in the clinic …

Systemic antiplatelet treatment represents a promising option to improve the therapeutic
outcomes and therapeutic efficacy of chemotherapy and immunotherapy due to the critical …

The growing insights in the complex interactions between metastatic cancer-cells and
platelets have revealed that platelet tumor cell interactions in the blood stream are an …

Cancer tissues are not just simple masses of malignant cells, but rather complex and
heterogeneous collections of cellular and even non-cellular components, such as …

Background In addition to their pivotal roles in coagulation and thrombosis, platelets are
crucial in tumor progression, with plenty of clinical and experimental data demonstrating that …

It has been confirmed that platelets play a key role in tumorigenesis. Tumor-activated
platelets can recruit blood cells and immune cells to migrate, establish an inflammatory …

Background Immune checkpoint inhibition is effective in several cancers. Expression of
programmed death-ligand 1 (PD-L1) on circulating tumor or immune effector cells could …